FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200499285> ?p ?o ?g. }

• W4200499285 endingPage "S771" @default.
• W4200499285 startingPage "S770" @default.
• W4200499285 abstract "Abstract Background MRSA remains an important cause of community-onset (CA) and nosocomial (NA)- SSSI. Oritavancin (ORI) is a lipoglycopeptide antibiotic with activity against S. aureus, including MRSA and multidrug-resistant (MDR) strains. ORI was approved for clinical use by the US FDA to treat ABSSSI with a single 1,200 mg infusion over 1 (Kimyrsa) or 3 (Orbactiv) hours. This study evaluated the activity of ORI against MRSA isolates causing SSSI from US medical centers. Methods A total of 3,792 S. aureus isolates were consecutively collected (1 per patient) from 31 medical centers in 2017-2019 and tested for susceptibility (S) to ORI and comparators using CLSI broth microdilution methods. Among 1,582 (41.7%) MRSA isolates, 1,379 (87.2%) were reported as CA-MRSA and 203 (12.8%) as NA-MRSA. CA-MRSA isolates were evaluated by resistance (R) subgroups, including clindamycin (CLI-R; n=283; 20.5%), levofloxacin (LEV-R; n=831; 60.3%), MDR (non-susceptible to ≥3 classes of agents; n=816; 59.2%), and extensively drug resistant (XDR; non-susceptible to ≥5 classes; n=47; 3.4%). Results Overall, ORI inhibited 99.9% of all S. aureus isolates at the susceptible breakpoint (≤0.12 mg/L; 99.9% of MSSA and 100% of MRSA; Table). S rates were generally comparable between NA-MRSA and CA-MRSA isolates for ORI (100%S) and linezolid (LZD, 100%S) but lower susceptibility was observed for NA-MRSA compared to CA-MRSA for CLI (71.9%S vs. 79.1%S), LEV (31.0%S vs. 39.4%S), and trimethoprim-sulfamethoxazole (TMP-SMX; 91.1%S vs. 96.9%S). ORI was active against MRSA (MIC50/90, 0.03/0.03 mg/L), regardless of infection status (NA, MIC50/90, 0.03/0.06 mg/L; CA, MIC50/90, 0.03/0.03 mg/L). ORI and LZD remained active (100%S) against all CA-MRSA subsets: CLI-R, LEV-R, MDR, and XDR. Limited activity of CLI (69.9%S) and LEV (13.1%S) was observed against MRSA and each R subset, whereas TMP-SMX had &gt;90%S for all MSSA, MRSA, and R subsets, except XDR. Conclusion ORI exhibited potent in vitro activity against MRSA, regardless of the infection onset or R subset, in contrast to many comparators that lack activity against both, CA-MRSA and NA-MRSA. This in vitro activity, combined with the infusion time options provided to clinicians, suggests ORI is a favorable agent for treating SSSI in the US caused by MRSA, including MDR and XDR strains. Disclosures Cecilia G. Carvalhaes, MD, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Cidara Therapeutics, Inc. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Pfizer, Inc. (Research Grant or Support) Helio S. Sader, MD, PhD, FIDSA, AbbVie (formerly Allergan) (Research Grant or Support)Basilea Pharmaceutica International, Ltd. (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support, Contract no. HHSO100201600002C)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support) Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support) Rodrigo E. Mendes, PhD, AbbVie (Research Grant or Support)AbbVie (formerly Allergan) (Research Grant or Support)Cipla Therapeutics (Research Grant or Support)Cipla USA Inc. (Research Grant or Support)ContraFect Corporation (Research Grant or Support)GlaxoSmithKline, LLC (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, LLC (Research Grant or Support)Nabriva Therapeutics (Research Grant or Support)Pfizer, Inc. (Research Grant or Support)Shionogi (Research Grant or Support)Spero Therapeutics (Research Grant or Support)" @default.
• W4200499285 created "2021-12-31" @default.
• W4200499285 creator A5014992940 @default.
• W4200499285 creator A5028735988 @default.
• W4200499285 creator A5041157580 @default.
• W4200499285 creator A5051510167 @default.
• W4200499285 creator A5089371529 @default.
• W4200499285 date "2021-11-01" @default.
• W4200499285 modified "2023-10-16" @default.
• W4200499285 title "1369. Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019)" @default.
• W4200499285 doi "https://doi.org/10.1093/ofid/ofab466.1561" @default.
• W4200499285 hasPublicationYear "2021" @default.
• W4200499285 type Work @default.
• W4200499285 citedByCount "0" @default.
• W4200499285 crossrefType "journal-article" @default.
• W4200499285 hasAuthorship W4200499285A5014992940 @default.
• W4200499285 hasAuthorship W4200499285A5028735988 @default.
• W4200499285 hasAuthorship W4200499285A5041157580 @default.
• W4200499285 hasAuthorship W4200499285A5051510167 @default.
• W4200499285 hasAuthorship W4200499285A5089371529 @default.
• W4200499285 hasBestOaLocation W42004992851 @default.
• W4200499285 hasConcept C176947019 @default.
• W4200499285 hasConcept C2777052132 @default.
• W4200499285 hasConcept C2777458120 @default.
• W4200499285 hasConcept C2778651397 @default.
• W4200499285 hasConcept C2778980435 @default.
• W4200499285 hasConcept C2779489039 @default.
• W4200499285 hasConcept C2780950330 @default.
• W4200499285 hasConcept C2781276175 @default.
• W4200499285 hasConcept C2781336494 @default.
• W4200499285 hasConcept C2781414143 @default.
• W4200499285 hasConcept C501593827 @default.
• W4200499285 hasConcept C523546767 @default.
• W4200499285 hasConcept C54355233 @default.
• W4200499285 hasConcept C71924100 @default.
• W4200499285 hasConcept C86803240 @default.
• W4200499285 hasConcept C89423630 @default.
• W4200499285 hasConceptScore W4200499285C176947019 @default.
• W4200499285 hasConceptScore W4200499285C2777052132 @default.
• W4200499285 hasConceptScore W4200499285C2777458120 @default.
• W4200499285 hasConceptScore W4200499285C2778651397 @default.
• W4200499285 hasConceptScore W4200499285C2778980435 @default.
• W4200499285 hasConceptScore W4200499285C2779489039 @default.
• W4200499285 hasConceptScore W4200499285C2780950330 @default.
• W4200499285 hasConceptScore W4200499285C2781276175 @default.
• W4200499285 hasConceptScore W4200499285C2781336494 @default.
• W4200499285 hasConceptScore W4200499285C2781414143 @default.
• W4200499285 hasConceptScore W4200499285C501593827 @default.
• W4200499285 hasConceptScore W4200499285C523546767 @default.
• W4200499285 hasConceptScore W4200499285C54355233 @default.
• W4200499285 hasConceptScore W4200499285C71924100 @default.
• W4200499285 hasConceptScore W4200499285C86803240 @default.
• W4200499285 hasConceptScore W4200499285C89423630 @default.
• W4200499285 hasIssue "Supplement_1" @default.
• W4200499285 hasLocation W42004992851 @default.
• W4200499285 hasOpenAccess W4200499285 @default.
• W4200499285 hasPrimaryLocation W42004992851 @default.
• W4200499285 hasRelatedWork W2018382434 @default.
• W4200499285 hasRelatedWork W2041005384 @default.
• W4200499285 hasRelatedWork W2050135536 @default.
• W4200499285 hasRelatedWork W2108737426 @default.
• W4200499285 hasRelatedWork W2125076516 @default.
• W4200499285 hasRelatedWork W2561816630 @default.
• W4200499285 hasRelatedWork W2600395641 @default.
• W4200499285 hasRelatedWork W2802210674 @default.
• W4200499285 hasRelatedWork W3108951046 @default.
• W4200499285 hasRelatedWork W4200499285 @default.
• W4200499285 hasVolume "8" @default.
• W4200499285 isParatext "false" @default.
• W4200499285 isRetracted "false" @default.
• W4200499285 workType "article" @default.